10-K: Mycotopia Therapies Inc. Reports Full Year 2023 Results, Shifts Focus to AI Robotics

Mycotopia Therapies, Inc. reports a net loss for 2023 and a shift in business strategy towards AI-powered robotics following the acquisition of Philon Labs assets.

Summary

• Mycotopia Therapies, Inc. reported a net loss of $1,181,347 for the year ended December 31, 2023, compared to a net loss of $2,611,869 in 2022.
• The company's general and administrative expenses decreased by 64% to $616,724 in 2023, due to cost-saving initiatives.
• Interest expense decreased by 35% to $564,623 in 2023, primarily due to lower debt discount amortization, but was offset by increased default interest on note payables.
• The company had $279,134 in cash and cash equivalents as of December 31, 2023, a decrease from $385,899 in 2022.
• Mycotopia's working capital deficiency increased to $3,968,589 as of December 31, 2023, from $378,614 in 2022.
• The company acquired assets from Philon Labs, including intellectual property related to the Phill Robot and Milky Way products, for $2,000,000 in preferred stock.
• Mycotopia is shifting its focus to using artificial intelligence in robotics to improve quality of life.
• The company's monthly operating costs averaged approximately $36,000 per month for the year ended December 31, 2023, excluding capital expenditures.
• The company has outstanding obligations of approximately $1.1 million relating to the payment of indebtedness due within one year.

Sentiment

Score: 4

Explanation: The document shows some improvement in financial performance but also highlights significant financial challenges and risks, including a large working capital deficiency and the need for additional financing. The shift in business strategy to AI robotics is a positive but unproven development.

Positives

• The company's net loss decreased significantly from 2022 to 2023.
• Operating expenses were reduced by 64% due to cost-saving measures.
• Interest expenses decreased by 35% year-over-year.
• The acquisition of Philon Labs assets provides a new direction for the company with AI-powered robotics.

Negatives

• The company experienced a net loss of $1,181,347 in 2023.
• The company's cash reserves decreased to $279,134 by the end of 2023.
• The working capital deficiency increased to $3,968,589.
• The company has $1.1 million in debt obligations due within one year.
• The company has a history of net losses and negative working capital.

Risks

• The company's ability to continue as a going concern is dependent on securing additional financing and developing profitable operations.
• The company has a significant working capital deficiency.
• The company has outstanding debt obligations of approximately $1.1 million due within one year.
• The company's internal controls over financial reporting were deemed not effective as of December 31, 2023.
• The company is subject to the risks associated with the development and commercialization of new technologies, including AI-powered robotics.

Future Outlook

The company plans to fund its operations with cash on hand and additional financing, focusing on integrating the acquired assets and developing AI-powered robotics.

Management Comments

• Management is devoting substantially all of its efforts to developing its business and raising capital.
• Management is actively pursuing additional equity financing through discussions with investment bankers and private investors.

Industry Context

The company is operating in the emerging psychedelic therapeutics market, which is projected to grow significantly, and is now also entering the AI-powered robotics market, which is also experiencing rapid growth. The company is attempting to leverage its existing relationships in the psychedelic space while pivoting to a new market.

Comparison to Industry Standards

• The company's financial performance is weak compared to industry standards, with significant losses and a large working capital deficiency.
• The company's shift to AI-powered robotics is a significant change in strategy and it is difficult to compare to other companies in the psychedelic space.
• The company's lack of revenue and reliance on external funding is a concern compared to more established companies in both the psychedelic and robotics industries.
• The company's internal control weaknesses are a concern compared to industry best practices.

Management Changes

Related Party Transactions

• The company had related party transactions with Ehave, Inc., including promissory notes and a stock purchase agreement.
• The company has an executive consulting agreement with its CEO, Benjamin Kaplan, which includes cash compensation, stock-based compensation, and potential bonuses.
• The company has accrued expenses for board compensation.

Stakeholder Impact

• Shareholders face the risk of further dilution if the company raises additional capital.
• Employees may be impacted by the company's shift in business strategy.
• Customers may benefit from the development of new AI-powered robotics products.
• Creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company plans to integrate the acquired assets from Philon Labs.
• The company plans to develop and commercialize AI-powered robotics products.
• The company plans to secure additional financing to fund its operations.

Key Dates

Keywords

Mycotopia Therapies, AI, Robotics, Psychedelics, Mental Health, Phill Robot, Milky Way, Financial Results, Asset Acquisition, Debt, Preferred Stock